Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Breast Neoplasms 134Neoplasms 112Polycystic Ovary Syndrome 66Prostatic Neoplasms 63Colorectal Neoplasms 51Carcinoma, Non-Small-Cell Lung 47Pain 40Carcinoma, Hepatocellular 35Lung Neoplasms 34Keratosis, Actinic 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Pain, Postoperative 26Neoplasm Metastasis 26Head and Neck Neoplasms 26Stomach Neoplasms 24Colonic Neoplasms 23Multiple Myeloma 22Brain Neoplasms 21Pancreatic Neoplasms 20Lymphoma, Follicular 19Leukemia 19Anemia 19Uterine Cervical Neoplasms 18Leukemia, Myeloid, Acute 18Infertility 18Leiomyoma 17Lymphoma, Non-Hodgkin 16Lymphoma 16Cancer Pain 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15

Interventions

nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Completed × Piebaldism × Clear all
NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Completed
57 enrolled 8 charts
GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡